News und Analysen
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Merck & Co., Inc. (NYSE: MRK) is one of the largest pharmaceutical firms in the world. The firm ranks fourth behind giants like Eli Lilly (NYSE :LLY) and Novo Nordisk (NYSE: NVO), with a market
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics
QuantumScape Pulls Back After July Surge: Is It Ready to Rebound?
After 13 years, QuantumScape Co. (NYSE: QS) is getting closer to the launch of its first commercial solid-state lithium-metal (SSLM) battery. Its announcement of the extended production
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, but the lowered full-year EPS 2024
Rivian is Heading Back to $10 or Lower: Here’s Why
Rivian (NASDAQ: RIVN) made progress on several fronts in Q2 and reached a pivotal quarter, at least in the eyes of its CEO. However, despite the good news, the stock price will return to $10 and
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Merck & Co. Inc. (NYSE: MRK) delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year
These 7 Stocks Surged Double-Digits and Have Double-Digits to Go
Earnings reports often catalyze big moves in a stock’s price; the bigger the move, the more conviction the market shows. Catalysts for these moves include better-than-expected results, gained
3 small-cap biotechs with potential breakthroughs in 2024
There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors. Many are still clinical-stage companies
3 companies that more than doubled analyst EPS estimates
Earnings season is well underway, and the winner-and-loser separation continues to grow. Of the companies that beat consensus analyst estimates, even fewer go well beyond and exceed analyst
American Superconductor faster than a speeding bullet on EPS beat
Megawatt-scale power resiliency solutions provider American Superconductor Co. (NASDAQ: AMSC) shares surged 40% on its Q3 2023 earnings report and upside guidance. The computer and technology
APRISCO ENERGY INDUSTRIES Joins Forces with MAXIMANCE 2030 LTD and BLUEGRACE ENERGY BOLIVIA in a Cooperation Agreement for REDD+ Initiatives
BARCELONA, SPAIN / ACCESSWIRE / January 15, 2024 / APRISCO ENERGY INDUSTRIES S.L., a Spain-based company dedicated to a fair and sustainable energy transition, has joined forces with
Merck, the Dow's hottest stock, gets set to report Q4 financials
Dow Jones Industrial Average (DJIA) stalwart Merck & Co., Inc. (NYSE:MRK) has momentum on its side heading into its February 1st earnings report.
Shares of the large cap pharmaceutical company
Are defensive sectors ready to outshine growth in 2024?
Defensive sectors are off to a better start to the new year than growth stocks, which dominated in 2023.
The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), which has both growth and
MAXIMANCE 2030 LTD Backs BlueGrace Energy Bolivia in Advancing Towards a Secure Model for Achieving UN Sustainable Development Goals (SDGs)
MAXIMANCE's endorsement boosts BLUEGRACE ENERGY BOLIVIA's global expansion, strengthening its international footprint and investment potential.
LONDON, UK / ACCESSWIRE / November 1, 2023 /
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets
Developmental biomedical device company PetVivo Holdings Inc. (OTCMKTS: PETV) makes pet medical devices and therapeutics. What kind of medical devices would pets need? Pacemakers? Artificial hearts
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Big pharmaceutical stocks, including Novartis AG (NYSE: NVS), Eli Lilly & Co. (NYSE: LLY), Merck & Co. (NYSE: MRK), and Novo Nordisk A/S (NYSE: NVO) have been outperforming the broader market
Want Clean Energy? Siemens May Be Pointing To A Breakout
Shares of Siemens Aktiengesellschaft (OTCMKTS: SIEGY) showcased a massive 78% rally after 2022, full of natural growth, paired with enriched multiples on these expanding financials. Today, Siemens
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction. It
Bayern-Index – Allzeithoch in greifbarer Nähe
Der BAIX – Bayerischer Aktienindex kann im laufenden Jahr zwar nicht ganz mit dem DAX® mithalten. Die Performance seit Jahresbeginn kann sich dennoch sehen lassen. Drei der fünf Top-Performer kamen
Siemens Energy – Flaute beim Aktienkurs birgt dennoch Investmentmöglichkeiten
Siemens Energy hat kürzlich den Auftrag zum Bau einer neuen Gigafactory für Wasserstoff-Elektrolyseure erhalten. Gemeinsam mit Air Liquid soll im Jahr soll 2027 der kommerzielle Betrieb starten und
Die meistgehandelten Produkte: Munich Re mit positivem Ausblick
Der Aktienmarkt zeigt sich aktuell uneinheitlich, da trotz eines Rekordhochs vor Wochen ein klarer Anstieg über die 19.000-Punkte-Marke ausgeblieben ist und die Kurse zwischen Verlusten und
Gut aufgenommene Zahlen bei Continental – beginnt jetzt der Höhenflug?
Der deutsche Autozulieferer Continental AG hat seit längerer Zeit wieder einmal gute Zahlen präsentiert. Die Aktie ist aufgrund dessen um über 15 Prozent gestiegen und hat den Abwärtstrend
Zalando – Fokus auf Rentabilität zieht Anleger an
Die Aktie von Zalando zeigte in den zurückliegenden Tagen relative Stärke gegenüber dem DAX®. Auch auf Jahressicht hat die Aktie des Online-Händlers knapp die Nase vorn. Katalysator war zunächst ein
RWE – Strompreis und solide Zahlen unterstützen
Die Aktie von RWE zählte in der zurückliegenden Woche zu den stärkeren Titeln im DAX®. Unterstützung bekam der Versorger unter anderem von den gestiegenen Strompreisen. Der Strompreis-Future Phelix
Die meistgehandelten Produkte: Anleger:innen bearisch im DAX®
Am Dienstag startete der DAX® mit leichten Gewinnen in den Handel. Der wichtigste deutsche Aktienindex stieg um 0,3 Prozent und erreichte 18.830 Punkte. Experten erwarten, dass der Index bald erneut